Literature DB >> 31879547

Oral L-carnitine and pregnancy: real opportunity for narcoleptic women?

Andrea Romigi1, Diego Centonze1.   

Abstract

Entities:  

Year:  2019        PMID: 31879547      PMCID: PMC6922543          DOI: 10.5935/1984-0063.20190060

Source DB:  PubMed          Journal:  Sleep Sci        ISSN: 1984-0063


× No keyword cloud information.
We read with great interest the case by Barros et al.[1] who described a young female with narcolepsy type [1] who replaced escitalopram (20 mg per day) and modafinil (400 mg per day) with L-carnitine 510 mg/d during pregnancy. The previous treatment induced a quite improvement of somnolence (Epworth Sleepiness Scale score 23/24 to 19/24) and cataplexy (10 episodes/d to 2 episodes per week). During pregnancy, L-carnitine induced a mild improvement of ESS score (20/24) and cataplexy (ten episodes per month). The authors stated that the patient had a good outcome, delivery and breastfeeding were without complications. We previously described a case of narcolepsy type 2, who started oral L-carnitine therapy up to 500 mg b.i.d.[2]. The patient obtained sustained objective (MSLT) and subjective (ESS) improvement until 6-month follow up after the delivery. Pregnancy is considered a physiological condition of L-carnitine deficiency[3] and its use during pregnancy is safe and may ameliorate pregnancy outcome[4]. In particular L-carnitine deficiency is involved during pregnancy in the state of resistance to the anorectic and thermogenic actions of hypothalamic cellular signals of energy surplus, which, added to refractoriness to leptin effects, likely contributes to gestational hypersomnia, hyperphagia, and obesity[3]. The same key areas and similar clinical symptoms were also reported in narcolepsy[5],[6]. Low serum level acylcarnitine were described in narcolepsy, and L-carnitine supplementation may reduce sleepiness[7],[8]. The partial improvement of ESS reported by Barros et al.[1] may be explained by a low dose of L-carnitine compared to our case (510 mg/d vs. 1000 mg/d)[2]. Since narcolepsy treatment during pregnancy is challenging[9], L-carnitine may represent a safe and effective treatment, although randomized controlled-study should confirm its efficacy on sleepiness and cataplexy and effective and safe dosages in larger sample.
  9 in total

1.  Oral L-carnitine as treatment for narcolepsy without cataplexy during pregnancy: a case report.

Authors:  Andrea Romigi; Claudio Liguori; Francesca Izzi; Maria Albanese; Angela Marchi; Cristiano Mancini; Enza Tarquini; Nicola Biagio Mercuri; Fabio Placidi
Journal:  J Neurol Sci       Date:  2014-11-26       Impact factor: 3.181

2.  Effects and pregnancy outcomes of L-carnitine supplementation in culture media for human embryo development from in vitro fertilization.

Authors:  Min Kyoung Kim; Jae Kyun Park; Soo Kyung Paek; Ji Won Kim; In Pyung Kwak; Hee Jun Lee; Sang Woo Lyu; Woo Sik Lee
Journal:  J Obstet Gynaecol Res       Date:  2018-08-01       Impact factor: 1.730

3.  Abnormally low serum acylcarnitine levels in narcolepsy patients.

Authors:  Taku Miyagawa; Hiroko Miyadera; Susumu Tanaka; Minae Kawashima; Mihoko Shimada; Yutaka Honda; Katsushi Tokunaga; Makoto Honda
Journal:  Sleep       Date:  2011-03-01       Impact factor: 5.849

4.  Pregnancy induces resistance to the anorectic effect of hypothalamic malonyl-CoA and the thermogenic effect of hypothalamic AMPK inhibition in female rats.

Authors:  Pablo B Martínez de Morentin; Ricardo Lage; Ismael González-García; Francisco Ruíz-Pino; Luís Martins; Diana Fernández-Mallo; Rosalía Gallego; Johan Fernø; Rosa Señarís; Asish K Saha; Sulay Tovar; Carlos Diéguez; Rubén Nogueiras; Manuel Tena-Sempere; Miguel López
Journal:  Endocrinology       Date:  2014-12-23       Impact factor: 4.736

Review 5.  Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure.

Authors:  Hooman Ganjavi; Colin M Shapiro
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

6.  Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time.

Authors:  Claudio Liguori; Fabio Placidi; Francesca Izzi; Marzia Nuccetelli; Sergio Bernardini; Maria Giovanna Sarpa; Fabrizio Cum; Maria Grazia Marciani; Nicola Biagio Mercuri; Andrea Romigi
Journal:  Sleep Breath       Date:  2016-01-23       Impact factor: 2.816

7.  Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies.

Authors:  Eszter Maurovich-Horvat; David Kemlink; Birgit Högl; Birgit Frauscher; Laura Ehrmann; Peter Geisler; Katharina Ettenhuber; Geert Mayer; Rosa Peraita-Adrados; Elena Calvo; Gert Jan Lammers; Astrid Van der Heide; Luigi Ferini-Strambi; Giuseppe Plazzi; Francesca Poli; Yves Dauvilliers; Poul Jennum; Helle Leonthin; Johannes Mathis; Aleksandra Wierzbicka; Francisco J Puertas; Pierre A Beitinger; Isabelle Arnulf; Renata L Riha; Maria Tormášiová; Jana Slonková; Sona Nevšímalová; Karel Sonka
Journal:  J Sleep Res       Date:  2013-04-08       Impact factor: 3.981

8.  Oral L-Carnitine used to treat narcoleptic type 1 patient during pregnancy - A case report.

Authors:  Felipe Barros; Ana Carolina Rodrigues Aguilar; Sergio Tufik; Fernando Morgadinho Coelho
Journal:  Sleep Sci       Date:  2018 Jul-Aug

9.  Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial.

Authors:  Taku Miyagawa; Hiromi Kawamura; Mariko Obuchi; Asuka Ikesaki; Akiko Ozaki; Katsushi Tokunaga; Yuichi Inoue; Makoto Honda
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.